SLAMF7 (Signaling lymphocytic activation molecule F7) also known as CS1 (CD2 subset 1), CRACC (CD2-like receptor-activating cytotoxic cell) and CD319, is a type I transmembrane protein and a member of the SLAM receptors family. SLAM receptors modulate the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. SLAMF7 is abundantly present in most cases of multiple myeloma (MM), a nearly universally fatal malignancy of plasma cells. Targeting SLAMF7 with Elotuzumab, a humanized mAb against SLAMF7 is approved for the treatment of relapsed MM. The anti-tumor effects of elotuzumab include disrupting MM cell adhesion to bone marrow stromal cells, enhancing NK cell cytotoxicity, and mediating antibody-dependent cell-mediated cytotoxicity (ADCC), but not complement-mediated cytotoxicity (CDC). SLAMF7 is also found on natural killer (NK) cells, activated T cells, most B cells and myeloid cells.
|Tissue Type/Cancer Type|
0.5 mL – Manual – Concentrate, 1 mL – Manual – Concentrate, 6 mL – Manual – RTU, 50 Tests – Automation – Xmatrx, 100 Tests – Automation – i6000, 200 Tests – Automation – Xmatrx, 5 slides – Xmatrx, 5 slides – Manual